Nutraceuticals - a natural part of modern healthcare  
ICMAN5
  Confirmed Speakers   Print  
  Prof Lindsay Brown - Faculty of Sciences, Biological and Phsyical Sciences, University of Southern Queensland 
In 2009, Lindsay became Professor of Biomedical Sciences at the University of Southern Queensland, after working at The University of Queensland as an academic since 1986. Lindsay is also Adjunct Professor at the College of Pharmaceutical Sciences, Manipal University, India. His research group is recognised for its studies on rat models that adequately mimic human cardiovascular and endocrine disease. They have used these rat models to determine whether interventions, either with selective drugs or natural products, can reverse or prevent disease-induced changes in structure and function, especially of the heart, liver, kidney and adipose tissue, to indicate whether these interventions should be tested in humans with these diseases. These studies have shown that selective anti-inflammatory compounds such as phospholipase A2 inhibitors as well as natural products such as olive leaf, purple carrots, chia seeds, piperine and rutin can prevent or reverse high carbohydrate, high fat diet-induced structural and functional changes in the heart, liver and kidney as well as reversing increased abdominal fat pad mass. These studies have been reported in major international scientific journals as well as in media appearances, mostly TV but also radio, on the cardiovascular and endocrine effects of food, nutritional supplements, and other natural products. Many of these recent studies on the potential of foods as medicines have been supported by their industry partner, Dr Red Nutraceuticals, Mt Nebo.
They have also studied interventions in rat models of hypertension and heart failure. In particular, they have shown that the ageing male SHR is the most appropriate model for testing drugs such as rosuvastatin and metoprolol that may prevent or reverse heart failure as this model accurately defines the changes in humans; and that the DOCA-salt hypertensive rat model is the most relevant model to evaluate drugs that decrease oxidative and inflammatory stress on the heart. Further, they now have promising results with diet-induced models of kidney damage showing that they can mimic the chronic damage to these organs in obese humans. These models will provide the basis for intervention studies with new selective compounds as well as with natural products.
 
 

Prof Les Cleland MB BS MD - Director of Rheumatology, Royal Adelaide Hospital and Clinical Professor, University of Adelaide 
Graduated MB BS and MD at the University of Adelaide. Director of
Rheumatology, Royal Adelaide Hospital since 1982. Clinical Professor, University of Adelaide since 2000. Long term clinical and research interests include the anti-inflammatory effects and cardiovascular benefits of long chain omega-3 fatty acids found in fish and fish oil. Professional interests also encompass systems for cost-effective, safe management of rheumatic diseases and the place of anti-inflammatory doses of fish oil therein. The extent of and mechanisms underlying the cardiovascular toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) has been a particular interest, along with strategies for utilising anti-inflammatory/analgesic doses of fish oil to avoid NSAID-related risks, through utilisation of medicinal doses of fish oil as an alternative  for the management of chronic musculoskeletal pain. Erstwhile appointments include President, Australian Rheumatology Association; Honorary Medical Director, Arthritis Australia; Member, Advisory Committee to Australian Government, Department of Health and Ageing for the National Health Priority for Arthritis and Osteoporosis; Member, Economics Subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. Contributions have been made to numerous journal and research funding review panels.  

 

 

Prof David Colquhoun - AMA Qld Cardiology Spokesman 
Associate Professor David Colquhoun is a Cardiologist in private practice.  He has been extensively involved in research over the last 25 years involving multi-centre international trials and investigator initiated trials in the area of lipids, nutrition, nutraceuticals and physiological aspects of heart disease, diabetes and obesity.  He has presented his research at many national and international meetings.  He is Head of Cardiovascular research at Greenslopes Private Hospital. He has a private research organization (CORE Research).  He was a member of the National Heart Foundation of Australia Nutrition and Metabolism Committee.  He is a grant assessor for National Health and Medical Research Council, National Heart Foundation Australia and Diabetes Australia.  He has published and been a referee for major journals.  He is the AMA spokesperson for Cardiology in Queensland.  He is a member of the Scientific Committee of National Institute of Complementary Medicine.  In 2008 he attended the 2020 Summit, the only cardiologist invited.  He was a member of the Queensland Government Smart State Council working group on Prevention and early intervention approaches to tackle chronic disease.  He was the Chief Author of the National Heart Foundation’s position statement on fish and fish oil in 2008. He writes a column for Prevention magazine.

 

  Dr Rohan Davis - Group Leader of the Natural Product Chemistry Team, Eskitis Institute for Cell and Molecular Therapies, Griffith University
Dr Rohan Davis obtained his B Science with Honours from the University of Melbourne (1992), and subsequently gained several years of industry experience working for AstraZeneca, Griffith University. Awarded a PhD from Griffith University in 2001, he then obtained 2 years post-doctoral experience at the University of Utah, Salt Lake City, USA. Returning to Griffith University in 2003 Dr Davis is currently Group Leader of the Natural Product Chemistry team at the Eskitis Institute of Cell and Molecular Therapies.

Dr Davis's research interests include:
1. Isolation and structure elucidation of bioactive natural products
2. Biodiscovery involving high throughput screening against molecular targets
3. Design and synthesis of libraries based on natural product scaffolds
4. Discovery of novel secondary metabolites from fungi
5. Identification of small molecule enzyme inhibitors using mass spectrometry

 

Prof Peter R. Ebeling MBBS MD FRACP - Chair, NorthWest Academic Centre and Assistant Dean, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne and Head of Endocrinology, at Western Hospital, Victoria, Australia.
Research interests include public health aspects of vitamin D; post-transplantation osteoporosis; osteoporosis in men; and biochemical bone turnover markers. He has served on the Editorial Board of Journal of Bone and Mineral Research since 2001 and is currently an Associate Editor. He also serves on the Editorial Board of Osteoporosis International and is Medical Director of Osteoporosis Australia and President-Elect, Endocrine Society of Australia; past-President of the Australian and New Zealand Bone and Mineral Society, and Councilor-Elect, American Society of Bone and Mineral Research, only the third Australian to be elected. He is on the NHMRC Academy (209-2011). He has over 160 peer-reviewed publications, including in the New England Journal of Medicine, PNAS (USA) and Science.

 

   

Prof Kobus Eloff - Research Professor, University of Pretoria
Jacobus Nicolaas Eloff has been a professor at Universities of Free State, Cape Town and Pretoria, Executive Director National Botanic Gardens (Head Office Kirstenbosch) and Research Director National Botanical Institute since 1972.  He is currently research professor and leader of the interdisciplinary Phytomedicine Programme in the Faculty of Veterinary Science at the University of Pretoria.
Professor Eloff has been the Scientific Editor of the South African Journal of Botany for 16 years and is the editor of 6 volumes of the Annals of Kirstenbosch Botanic Gardens, African Herbal Pharmacopoeia and Green Gold.  He is presently the  Executive Editor of the South African Journal of Natural Science and Technology, Editor-in Chief of the International Journal for Phytomedicine and a member of the Editorial Panel of the South African Journal of Botany, African journal of Traditional, Complementary Alternative Medicine and Evidence-Based Complementary and Alternative Medicine.  He has presented more than 150 papers at international scientific conferences and has more than 160 peer reviewed scientific publications.   He received the Senior Medal for Botany from the South African Association of Botanists and honorary life membership in January 1993 and Volume 65 (1999) of the South African Journal of Botany was dedicated to him.  He received the Havenga Prize for outstanding research in Biological Sciences from the Suid-Afrikaanse Akademie vir Wetenskap en Kuns in 2003, the Bronze medal from the International Horticultural Society in recognition of organizing the World Conference on Medicinal and Aromatic Plants (WOCMAP IV) in 2008 and the Gold medal of the Suid-Afrikaanse Akademie vir Wetenskap en Kuns for discoveries with important practical applications in the medicinal plant field in 2009.  He also has several patents based on his group’s research.
He was appointed by the European Union’s Centre for the Development of Enterprise to develop Pan-African quality control standards and monographs for African Medicinal plants which led to the production of the African Herbal Pharmacopoeia. 

 

 

Prof Michael Fenech - Principal Research Scientist, CSIRO Food and Nutritional Sciences
Professor Michael Fenech is recognised internationally for his research in nutritional genomics and genetic toxicology and for developing the cytokinesis-block micronucleus (CBMN) assay which is now a gold standard method used internationally to measure DNA damage in human cells in vitro and in vivo. His key goal is to determine the nutritional and environmental requirements for DNA damage prevention using in vitro systems, epidemiology and placebo-controlled human intervention trials. In 2003-05, Dr Fenech proposed a novel disease prevention strategy based on personalised diagnosis and prevention of DNA damage by appropriate diet/life-style intervention, which has led to the Genome Health Clinic concept and its translation into practice (www.reach100.com.au). In 2003-2009 his laboratory further developed the CBMN assay into a 'cytome' assay consisting of six complementary biomarkers of DNA damage and cytotoxicity which is now published in Nature Protocols. He co-founded the ongoing HUMN and HUMN-XL projects on micronuclei in human populations (www.humn.org) and is a member of the coordinating group for the Micronutrients Genomics Project (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989004/) which he will be leading from July 2011. His research is currently also focussed on the impact of nutrition on telomere length and function; he conceived and developed, together with other scientists in his group, a novel quantitative PCR method for measuring absolute telomere length. He was awarded the Flinders University’s Convocation Medal in 2007, the Alexander Hollaender Award (USA) in 2008 and the honorary titles of Adjunct Professor (University of South Australia) in 2009 and Visiting Professor (Taipei Medical University, Taiwan) in 2010 for his leadership/contributions to environmental/public health sciences internationally. His 210 publications have been cited 8,500 times and his H-index is 48.

 

 

Prof Juerg Gertsch - Professor at the Institute for Biochemistry and Molecular Medicine, University of Bern
Jürg Gertsch studied Cultural Anthropology at the Central University (UCV) in Caracas, Venezuela before he studied Neurosciences and Biochemistry at the University of Sussex, England and the University of Basel, Switzerland. He obtained an MSc in Biochemistry in 1997.  Between 1998 and 2002, he carried out an interdisciplinary research project with a focus on bioactive natural products and ethnobotany at the ETH (Swiss Federal Institute of Technology) in Zurich, Switzerland.  During that time he did field work among the Yanomami Amerindians in Venezuela. After postdoctoral research at the Institute of Pharmaceutical Sciences he became a senior scientist at the Department of Chemistry and Applied Biosciences ETH Zurich. Since 2009 he is a Professor at the University of Bern at the Institute of Biochemistry and Molecular Medicine where his group currently works on the pharmacology of different classes of natural products, with a special focus on the endocannabinoid system, microtubule-interacting compounds and transporters. His major focus is immunopharmacology.  Gertsch is a PI at the NCCR TransCure, a Swiss MC member for the COST Action 0804 "Chemical Biology with Natural Products". He has presented more than 150 papers at international scientific conferences and has more than 60 peer-reviewed scientific publications. In recognition to his work on natural product pharmacology he received the 2010 Dr. Willmar Schwabe award (Berlin, Germany) and for his work on cannabinoids he obtained the Young Investigator Award Cannabinoids in Medicine 2010 (Jerusalem, Israel).

  Tomi Hamalainen - Jamix Australia
Tomi Hamalainen (B.E.) has over 30 years’ experience in the telecoms, internet technologies and small business solutions with main experience in sales, technical and business development across 40 countries.
Since 2001, Tomi has worked full-time in developing new technologies in small business in a variety of roles including his latest role as the Australian and New Zealand distributer for Finnish company, Jamix providing food service management and nutrition technology. He manages and develops food service software solutions for aged care, child care, mining, restaurant and university clients.
Prior to working in the food service industry, he has worked with high-tech companies such as Sonera Finland, Sprint and Cisco Systems developing new solutions in internet and VoIP with the latest technologies in Finland, USA and Australia. He holds a B.E. in electrical engineering from the James Cook University (Townsville), a marketing course at Berkeley University and has attended numerous international conferences as a speaker in new technologies.

 

Prof Michael Heinrich - Director of Southern Cross Plant Science Centre, Southern Cross University, Australia
Professor Michael Heinrich is a pharmacognosist, biologist and anthropologist specializing in medicinal and food plant research, especially bioactive natural products as well as food and medicinal plant usage (ethnopharmacology), previously in Mexico and the Mediterranean. He is currently Director of Southern Cross Plant Science Centre at Southern Cross University and leads a team working across a range of research and commercial platforms including metabolomics / phytochemistry, phytopharmacology, ethnobiology, DNA technologies, genomics, plant improvement and bioinformatics. 
Michael has edited and co-authored five books on medicinal and food plant research and published over 180 refereed scientific papers and a large number of international conference papers.
For many years he has worked on bioactive secondary metabolites from plants with a particular focus on anti-inflammatory compounds using the transcription factor NF-kappaB as a key lead. Some more recent examples of projects include: Metabolomic research on medicinal and other plants, the use of herbal medicines in migrant communities in London, history of medicinal plant use in Europe and food and medicinal plant usage in the Mediterranean. Recent research projects centre on the value chain between producers and consumers of herbal medicines and food supplements.

 

 

Dr. Zdenko Herceg - Group Head - Epigenetics Group at International Agency for Research on Cancer, Lyon, France
Zdenko Herceg is a molecular biologist and geneticist with a specialization in epigenetics and cancer research. He is currently Head of the Epigenetics Group at the International Agency for Research on Cancer (Lyon, France) and leads a team that conducts both mechanistic studies and epigenetic profiling, aiming to better understand tumorigenesis and to discover and validate new epigenetic biomarkers. His laboratory exploits new concepts in cancer epigenetics and recent technological advances in epigenetics and epigenomics, and the work is carried out in close collaboration with national and international groups. Prior to joining IARC, in 1997, he was a post-doctoral scientist at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria. He earned his Ph.D. in 1995 from the University of St Andrews (UK) in the field of oncogenic transformation of human epithelial cells. He has authored a number of publications in the field of epigenetics, mechanisms of carcinogenesis and cancer research. His recent research projects are designed to gain a better understanding of epigenetic mechanisms in human cancer and provide critical information for the development of novel epigenetics-based strategies for cancer prevention. More information on his Group can be found at: http://www.iarc.fr/en/research-groups/EGE/staff.php

 

Prof Peter Howe - BSc, MSc, PhD, RNutr, FNSA School of Health Sciences, University of South Australia
- Research Professor in Nutritional Physiology 
- Human Research Ethics Advisor in Health Sciences
- Adjunct Professor in Physiology, University of Adelaide
- Formerly Senior Principal Research Scientist, CSIRO Division of Human Nutrition; 
- Professor in Biomedical Science and Director of Smart Foods Centre, University of Wollongong
- An authority on cardiovascular and metabolic health benefits of bioactive nutrients.
- Research goal: scientific substantiation and promotion of health benefits of functional foods and nutraceuticals.
- 190 publications; 4000 citations; H-Index = 31
- Founded major research collaborations: Nutritional Physiology Research Centre,
- University of South Australia, Smart Foods Centre, University of Wollongong (ARC Key Centre of Teaching and Research), ATN Centre for Metabolic Fitness
- Established strategic alliances with both primary producers and food manufacturers to develop healthier foods.
- Fellow of the Nutrition Society of Australia
- Editor-in-Chief of 'Nutrients'

 

 

Dr Peter Jones PhD – Director, Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba
Peter J. Jones, the Canada Research Chair in Functional Foods and Nutrition, joined the University of Manitoba on November 1, 2005, as Director of the Richardson Centre for Functional Foods and Nutraceutical.  His main appointment is in the Department of Food Science with a cross-appointment in Human Nutritional Sciences.
A native of Vancouver, Dr. Jones received a BSc degree in Biochemistry at the University of British Columbia. He obtained a MSc in Human Nutrition also at UBC before completing a PhD in Nutritional Biochemistry from the University of Toronto in 1985. After two years with the Clinical Nutrition Research Center at the University of Chicago, as a post-doctoral fellow, Dr. Jones was on faculty with the Division of Human Nutrition at UBC. He was the Director of the School Dietetics and Human Nutrition at McGill University from 1994-1999; in addition to being a professor in the school and holding a cross-appointment in the Department of Medicine until 2005.
Currently, Dr. Jones serves as President of the Danone Institute for Nutrition in Canada and Past-President of the Canadian Society for Nutritional Science. He serves as Chairman of the Functional Foods and Nutraceuticals Board of the Forbes Medi-tech group and has also sat on the Food and Agriculture Organization of the UN World Health Organization, and UN University (FAO/WHO/UNU) Expert consultant Panel for Energy and Protein Requirements in Human Nutrition.
Dr Jones' research includes cholesterol, fat and energy metabolism. His research group has been active in exploring the dietary determinants which control cholesterol biosynthesis absorption, and turnover in humans, and how plant sterols act in functional foods as cholesterol-lowering agents. Other research areas include re-establishing energy needs in sub-groups of the Canadian population and exploring which fats confer optimal health during weight reducing diets. Dr Jones has published over 270 peer-reviewed research articles and reviews in international journals, as well as chapters in leading nutrition textbooks.

 

 

Prof Michael KimlinDirector, NHMRC Centre for Research Excellence in Sun and Health; Director, AusSun Research Lab, Queensland University of Technology
Professor Kimlin has held academic appointments in the USA and Australia undertaking research into the impact of surface UV levels, stratospheric ozone and human health (Vitamin D and skin cancer). Based at the University of Georgia in the USA, he was the scientific director of the world's largest ozone/UV network with over 21 Brewer Spectrophotometer monitoring sites located throughout the USA. He has obtained over $8.9 Million in research grants (both in Australia and the USA), published over 100 refereed publications. Professor Kimlin returned to Australia on the Queensland Government's "Smart State Fellow" initiative, and is continuing his research into human UV exposure, Vitamin D and skin cancer prevention based at the Queensland University of Technology where he is currently the Director of the NHMRC Center for Research Excellence in Sun and Health.

  Dr Izabela Konczak - Senior Research Scientist, CSIRO Food and Nutritional Sciences Division, Australia
Izabela is a Senior Research Scientist at the CSIRO Food and Nutritional Sciences Division, Australia, researching bioactive phytochemicals for use in pharmaceutical, nutraceutical and food industries. Her research expertise involves: extraction, purification, identification of phytochemicals, development of laboratory assays for evaluation of potential physiological activities (antioxidant, anticancer, antimutagenic, antidiabetic) and understanding their mechanism of action. Her experience has been generated through PhD studies and extensive post-doctoral research at the Polish Academy of Sciences (Poland), Miyazaki University (Japan), Crop & Food Research Institute (New Zealand), Kyushu-Okinawa National Agricultural Research Centre (Japan), Ohio State University (USA), Nagoya University (Japan). She joined the CSIRO in 1999, where she has established a research program aiming at understanding the health attributes of native Australian plants. Izabela has authored one commercially applied technology (New Zealand) and four patents (2 in Japan and 2 in Australia), over 40 research papers in international peer-reviewed journals and over 50 presentations at international conferences. She is the founder of the “International Workshop on Anthocyanins” series originally hold in Australia (year 2000, 2002 and 2004), followed by events in New Zealand (2006), Japan (2009) and USA (September, 2011).
  Dr Rod Lea - Genetic Epidemiologist, Griffith Health Institute
Rod has specialist expertise in experimental design and the statistical analysis of public health, clinical and biomedical studies involving molecular genetic data.  These skills have been applied to research aimed at understanding the genetic basis of complex human diseases including migraine, cancer, hypertension and multiple sclerosis.  Current research activities include developing and applying new computational methods to identify the envirogenomic interactions that influence disease risk and response to medicine.  The goal of Rod's research is to identify personalised profiles that can be used diagnostically for more accurate prediction of clinical outcomes of a range of issues in human health.
 

Associate Professor Rachel Neale - Cancer Epidemiologist and Senior Research Fellow, Queensland Institute of Medical Research
After completing a PhD in Queensland in the late 1990s she spent several years honing her research skills at the Universities of Cambridge and Oxford in the United Kingdom. Her research focuses primarily on causes of cancers of the pancreas and the skin. She is a member of the Centre for Research Excellence in Sun and Health (funded by the National Health and Medical Research Council) which aims to conduct high quality research that will enable the development of public health messages that balance the harms and the benefits of sun exposure. A/Prof Neale is chair of the multisectoral Skin Cancer Prevention Working Group, and is currently conducting a pilot trial of vitamin D supplementation for the reduction of mortality in Australia.

 

 

Dr Anthony Noble - Director - Special Projects, Soho Flordis International
Anthony’s role at Soho Flordis International is as Director of Special Projects, with responsibility for the logistics and relationship management involved in doing business in 16 markets around the world. Anthony coordinates new product development and new market entry for SFI and manages collaborations with research teams in Australian and international universities through activities ranging from grant application planning to product development and commercialization of finished products. Anthony is responsible for planning and implementing high priority projects in key markets around the world in addition to more than 20 Australian based projects, through coordinating and guiding managers and external stakeholders. Anthony has significant experience as a project and general manager in the biotechnology industry.  He has previously held roles as both Principal Scientist and Marketing Manager for the Australian Cord Blood Service (Cryosite Ltd) and as Regulation Manager and Lead Inspector for the Human Tissue Authority (London, UK). Anthony’s background is in Cell Biology and he held Product Development and Project Management roles in the Institute for Health and Biomedical Innovation at the Queensland University of Technology before moving to the private sector.

 

  Anastasia Ossoukhova- PhD Student, Swinburne Centre for Human Psychopharmacology, Swinburne University of Technology
Anastasia graduated from the Moscow State University with 1st Degree Honours in Psychology/Psychophysiology, where she worked on the project looking into the effects of induced stress on slow components of the visual ERP. Since coming to Australia developed  strong interest towards alternative herbal treatments of various health problems. Anastasia is currently working on PhD project investigating the effects of Selected botanicals on Cognition and Glucoregulation. 

 

Dr Ashfaq Parkar - Director Transformational Sciences, Sanofi-Aventis
Ashfaq Parkar works at Sanofi Aventis, USA, where he holds the position of Director, Transformational Sciences. Until recently his focus in the pharmaceutical industry has been on small molecule R&D. He is currently focussed on the application of R&D principles from the pharmaceutical industry to the advancement of botanical drugs.

 

 

Prof Ron Quinn AM - Director, The Eskitis Institute for Cell and Molecular Therapies, Griffith University
Professor Quinn obtained his PhD from the University of New South Wales(Australia) in 1970. Following post-doctoral research at Arizona State University, University of Hawaii, and ANU, he joined the Roche Research Institute of Marine Pharmacology in Sydney (1974 – 1981). He joined Griffith University in 1982 and is the Foundation Director of the Eskitis Institute for Cell and Molecular Therapies at Griffith University. He is the author of over 170 publications and patents. His research concentrates on the use of molecules as tools to understand interactions in biological systems and to build concepts around molecular recognition. His research has concentrated on:
1. Biodiscovery involving high throughput screening against molecular and cellular targets, isolation and structure elucidation of bioactive natural products
2. Design and synthesis of receptor ligands in the adenosine area, enzyme inhibitors of protein phosphatase 1 and 2A and Factor XIa
3. Understanding of natural product recognition for biosynthetic enzymes and correlation with therapeutic targets as a rational approach to drug discovery and
4. Developing concepts of biological structure space embedded in natural product scaffolds.
His research has included development of Nature Bank as a state-of-the-art resource for biodiscovery. Nature Bank is a unique library of 200,000 fractions, containing drug-like natural products, derived from a collection of over 45,000 samples of plants and marine invertebrates collected from mega-diverse areas.
The current direction of his research is to transform approaches to the discovery of new bioactive molecules from nature. He has developed a front-loading of physicochemical properties of constituents of extracts and is using an understanding of biological structure space to discover new biologically relevant molecules. Through funding from the Gates Grand Challenge Exploratory grant, he is developing a novel approach to study latent stages of malaria using natural product fragments. He was made a member of the Order of Australia in 2010 for his service to scientific research, in the field of chemistry as a leader in the development of therapeutic compounds from marine organisms and plant materials. He is a Fellow of the Australian Academy of Technological Sciences and Engineering and received the Adrien Albert Award from the Royal Australian Chemical Institute (RACI) in 2004.

 

 

Prof Avni Sali - Director, National Insitute of Integrative Medicine
Professor Avni Sali is the Founding Director of the Australian National Institute of Alternative Medicine  and the President of the International Council of Integrative Medicine. He was the Founding Head of the Graduate School of Integrative Medicine at Swinburne, University and was Head of the University of Melbourne Surgery Department at the Hedelberg Hospital. Professor Sali is the immediate past President of the Australasian Integrative Medicine Association.

 

 

Prof Dr Dieter Schinzer - DC Chair, COST
International Career
Since 2006: Domain Chair of Chemistry and Molecular Sciences and Technologies (CMST) at European Cooperation in Science and Technology (COST) in Brussels, Belgium
 
Professional Career
Since 2002: CEO of MOLISA GmbH, Magdeburg, Germany
2001: Offer of Professorship, University of Oslo, Norway
2002 - 2005: Dean of Faculty of Process and Systems Engineering, University of Magdeburg, Germany
Since 1998: Professor of Chemistry, University of Magdeburg, Germany
1991 - 1997: Associate Professor of Chemistry, University of Braunschweig, Germany
1990: Visiting Professor of Chemistry, University of Wisconsin, Madison, USA
1989 - 1990: Professor of Chemistry, University of Göttingen, Germany (temporary position)
1986 - 1989: Heisenberg Fellow (Deutsche Forschungsgemeinschaft, DFG), University of Hannover, Germany
1983 - 1986: Liebig Fellow (Fonds of Chemical Industry), University of Hannover, Germany
1980 - 1982: Feodor Lynen Fellow (Alexander v. Humboldt-Foundation), University of California, Berkeley, USA
 
Education 
1986: Habilitation, University of Hannover, Germany
1980: Doctoral Degree (Dr. rer. nat.), University of Bonn, Germany
1977: Diploma Degree (Dipl.-Chem.), University of Marburg, Germany

 

 

Prof Andrew Scholey - BSc (Hons) PhD CPsychol AFBPsS, Director of the Centre for Human Psychopharmacology, Swinburne University, Melbourne
Prof Andrew Scholey is director of the Centre for Human Psychopharmacology  at Swinburne University, Melbourne. He is a leading international researcher into the neurocognitive effects of natural products, supplements and food components, having published over 100 peer-reviewed journal articles and numerous book chapters. He is Professor of Brain and Behavioural Sciences and co-director of the NICM Collaborative Centre for the Study of Natural Medicines and Neurocognition. In 1998, he established the Human Cognitive Neuroscience Unit at Northumbria University, UK and was the Unit’s director until joining the then Brain Sciences Institute at Swinburne University in 2007. Professor Scholey was also co-director of the UK’s Medicinal Plant Research Centre and remains as honorary director of Neurocognitive trials.

 

 

Dr Jeffery Smith PhD, MBA - CEO, BioAssayLINK Pty Ltd
Jeffery Smith has over 30 years’ experience in basic and applied biomedical research and development encompassing discovery and early preclinical studies to first in human and investigator-driven clinical studies. 
Since 2001, Jeffery has worked full-time in the biopharmaceutical industry in a variety of roles including as a senior scientist of a US based biotech start-up, as an independent consultant and since 2006 as the founder of BioAssayLINK; online linking service for discovery and preclinical research services. He has undertaken work with numerous biotechnology and nutraceutical companies and small and large biopharmaceutical organizations. He is a contributor to a soon-to-be-published book entitled Pharmaceutical outsourcing: discovery and preclinical perspectives and is an advocate for online linking tools that improve efficiency and cost effectiveness of therapeutic research and development. 
Prior to working in the biopharmaceutical industry, he has undertaken basic and applied biomedical research in a variety of research institutions including The University of Queensland (UQ, Brisbane), The University of California (San Francisco), The University of Paris (Orsay) and The Queensland Institute of Medical Research (QIMR, Brisbane). He has published more than 30 peer-reviewed research papers and has broad interest and knowledge across most biomedical disciplines. He holds a visiting scientist position at QIMR and an adjunct senior lecturer position at UQ. He holds a BSc in biochemistry-chemistry from the James Cook University (Townsville), a PhD in biochemistry-surgery from UQ, and an MBA from the UQ Business School. 
 

 

Prof. Maree Smith - Executive Director, TetraQ
Professor Maree Smith is the Executive Director of the Centre for Integrated Preclinical Drug Development (CIPDD) at The University of Queensland that operates a commercial arm, TetraQ, that provids contract preclinical R&D services to clients in the biopharmaceutical industry in a quality systems accredited environment (ISO 17025 and GLP). CIPDD researchers work on collaborative research grant funded applied projects with Industry and academic partners targeted to bringing innovation into new drug development methods and/or assisting in moving drug discoveries along the development path towards commercialization.

Prior to taking up her current appointment as Executive Director of the CIPDD in 2005, Professor Smith was a full-time academic in the School of Pharmacy for 15 years and she has extensive expertise and know-how in the pain research field as well as in bioanalysis, pharmacokinetics and drug metabolism.  During those years, she gained considerable experience in the undertaking of contract R&D studies for a range of biotechnology companies as well as commercialization of her own intellectual property.
In 2003, Prof Smith was awarded a “Trailblazer Challenge” award by UniQuest. In 2008 she received the Women in Technology Biotech Outstanding Achievement Award and in 2009 she was conferred with Honorary Fellowship of the Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists.

 

 

Dr Michael Smith - Michael J Smith and Associates
Michael Smith is trained both as a pharmacist and a licensed naturopathic practitioner (Canada) with over 15 years of experience in the Natural Health Product/ Complementary Medicine sector. From May 2009 to Feb 2011 he was Head, Office of Complementary Medicines in the Therapeutic Goods Administration responsible for the management of the Australian regulatory framework for complementary medicines. Before that, he was the Director of the Bureau of the Partnerships, Outreach and International Affairs, Natural Health Products Directorate in Health Canada. His responsibilities there included establishing and implementing the Natural Health Products Research Program (NHPRP); co-ordination of the directorate’s international responsibilities; and responsibility for outreach activities with stakeholders and the creation of strategic partnerships with organisations and partners both within and outside of government. Michael has actively worked on the international stage notably in the creation of the International Regulatory Collaboration of Herbal Medicines (IRCH), strategic planning initiatives managed by the Western Pacific Region Office of the WHO and participated in numerous working groups and seminars. In 2009, The World Health Organisation appointed him to the Expert Advisory Panel on Traditional Medicines. Before joining the Federal Canadian Government, he was Associate Dean of Research at the Canadian College of Naturopathic Medicine and as such very active in Natural Health Product and Complementary and Alternative Health Care (CAHC) research notably concerning drug interactions and herbal medicines. Michael was also very involved in developing NHP and CAHC focussed education programs aimed both at members of the conventional and complementary health care teams. He is the author and co-author of numerous papers including publications in the Annals of Internal Medicine and Archives of General Psychiatry and articles as well as two books.

 

 

Professor Con Stough - Professor of Cognitive Neurosciences, Swinburne Centre for Psychopharmacology and Professor of Psychology at Swinburne University
Professor Con Stough is Professor of Cognitive Neurosciences at the Swinburne centre for Psychopharmacology and Professor of Psychology at Swinburne University. He is a leading researcher in the area of natural drugs, cognition, mood and the brain. He co-founded the Herbal and Nutraceutical Research Unit at Swinburne University and is the current Director of the National Institute of Complementary Medicine (NICM) collaborative research centre in neurocognition and herbal medicines which s part of the Centre for Human Psychopharmacology. More recent work has been in large pharmacological trials for the prevention of cognitive and brain aging and supplementary treatments for abnormal aging such as Alzheimer’s Dementia.

 

 

 Prof Young Joon Surh Professor of the Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University
Dr. Young-Joon Surh is a Professor at the College of Pharmacy, Seoul National University and Head of National Research Laboratory of Molecular Carcinogenesis and Chemoprevention supported by Ministry of Education, Science and Technology, South Korea. Dr. Surh earned his PhD degree at the University of Wisconsin-Madison and completed his postdoctoral training at the Massachusetts Institute of Technology. In 1992, he was appointed as a tenure-track assistant professor at Yale University School of Medicine. Since relocating to Seoul National University in 1996, Dr. Surh has been investigating cancer preventive and cytoprotective effects of phytonutrients and their underlying molecular mechanisms. He is/has been a member of the editorial boards of about 20 international journals, including Carcinogenesis, International Journal of Cancer, Molecular Carcinogenesis, Cancer Letters, Mutation Research, Life Sciences, Molecular and Cellular Biochemistry, Free Radical Research,  Food and Chemical Toxicology, Biofactors, Genes and Nutrition, Molecular Nutrition and Food Research, Journal of Clinical Biochemistry and Nutrition, etc.  He is also editor of the following books: Oxidative Stress, Inflammation and Health (CRC Press), Molecular Targets and Therapeutic Use of Curcumin (Springer-Veralg), and Dietary Modulation of Cell Signaling Pathways (CRC Press). Dr. Surh has published more than 200 papers in peer-reviewed international journals and about 60 invited editorials, reviews and book chapters. He received numerous awards including 2009 McCormic Science Institute Award from American Society for Nutrition. He published a seminal review article, titled cancer chemoprevention with dietary phytochemicals, in Nature Reviews Cancer which has been cited more than 500 times.

 

 

Dr. Koraljka Gall Trošelj - Senior Scientist, Rudjer Boskovic Institute
Dr. Gall Trošelj,  M.D., Ph.D., is a Senior Research Associate at the Rudjer Boskovic Institute in Zagreb, Croatia  and an Associate Professor at the University of Rijeka, Croatia. She has been involved in cancer research since  coming to the RBI in 1991. Dr. Gall Trošelj is a Fulbright Scholar and has spent two years at the Weill Cornell Medical School in New York City. One of her scientific interests is cancer chemoprevention by natural compounds, through targeted remodelling of the epigenomic network.

  Dr. Shaikh Uddin - School of Pharmacy, Griffith University
Shaikh received his undergraduate degree in Pharmacy with first class honours in 2004 from Khulna University, Bangladesh. Later he was engaged in teaching and research in Pharmacy Discipline, Khulna University, Bangladesh. In 2007, Shaikh moved to Australia for his PhD degree at School of Pharmacy, Griffith University and recently (May, 2011), he received his PhD degree. His PhD research was carried out under the guidance of Dr Evelin Tiralongo in the field of natural product chemistry and pharmacology. Since his undergraduate project, he explored a number of Bangladeshi medicinal plant extracts for their different biological activities and isolated a number of bioactive compounds from these plants. Currently, Shaikh is working as a research fellow in Dr Evelin’s group and engaged in research on discovery of novel anticancer compounds from Australian indigenous mushrooms.
 

Dr. Vasundara Venkateswaran M.Sc., M.Phil., Ph.D. - Associate Professor, Department of Surgery, University of Toronto, Division of Urology
Dr. Vasundara Venkateswaran obtained her Ph.D from the University of Madras, India. She has had several years of research training at the Washington State University and the University of Kansas Medical Centre, USA. She was recruited to the Division of Urology, Sunnybrook Health Sciences Centre in 2000 and was subsequently appointed as Assistant Professor, Department of Surgery, University of Toronto and Scientist, Division of Urology, Sunnybrook Health Sciences Centre in 2003. She received her promotion to Associate Professor in 2011.

Dr. Venkateswaran is responsible for the setting up and management of the prostate cancer research laboratory since 2000. She has established a major initiative in the study of the cellular effects of micronutrients in prostate cancer.   This initiative essentially started from scratch, has resulted in a burgeoning research program. Dr. Venkateswaran runs her initiative at the Prostate Cancer Research Laboratory that comprises of clinicians, fellows and Graduate students. 
Dr. Venkateswaran is the Director of the Summer Undergraduate Research Program at the Institute of Medical Sciences at the University of Toronto. She has a number of key publications in the field of micronutrients and prostate cancer in high impact peer reviewed journals. She has also presented her findings at several national and international meetings. Dr. Venkateswaran has established very productive collaborations with investigators throughout North America as well as locally in Toronto. She serves on the Editorial board of reputed journals. She has been highly successful in receiving peer reviewed operating grant support from the CIHR, PCC and CPCRI and NCIC.
Research Interests: Dr. Venkateswaran’s research interests are in the area of Translational research, Clinical Biochemistry and Molecular and cell biology. Her focus is on the cellular effects of diet, macronutrients and micronutrients including lifestyle, with an aim at recognizing novel strategies for improvement of early detection, diagnosis and chemoprevention of prostate cancer. Specifically, she is studying the mechanisms involving the androgen receptor and the IGF signalling pathways and the role of micronutrients in enhancing the effect of hormonal and chemotherapeutic drugs used for prostate cancer prevention.

 

Prof Moussa Youdim - Director, Eve Topf and US National Parkinson Foundation
Moussa Youdim was Chairman  and Professor  of Pharmacology from 1977 to 1994. and is full professor of Pharmacology and Finkelstein Professor of Life Sciences  at the Technion- Rappaport Family Faculty of Medicine . He is  the Director of the Eve Topf  and National Parkinson Foundation (USA) Centers of Excellence for Neurodegenerative Diseases at Technion. He holds the position of Distinguished Chair Professor  at Hong Kong and PolyTechnic Universities in Hong Kong,  Distinguished Scientific Professor at Yonsei University in Seoul , South Korea,  Honorary Distinguished Professor at Qingdao University and Shanghai Materia Medica University in China. He  is  internationally renowned for his research on monoamine oxidases and its identification of two forms in 1965 as part of his Msc. Degree and went on to purify the enzyme in 1n 1966 that this enzyme contained a covalentlt bound FAD as a cofactor. in drug development for  Depressive illness, Parkinson’s disease (PD) Alzheimer’s disease, Huntington disease  and for establishing the importance of  monoamine oxidase and brain iron metabolism for brain function and aminergic  and cholinergic neurotransmission and neurodegtenration. At Oxford University he  with his colleagues they  discovered  the monoamine  oxidase B inhibitor, l-deprenyl (selegiline) as an anti Parkinson drug in 1975 and  at Technion the  neuroprotective -disease modifying  anti-Parkinson drug, Rasagiline (Azilect) . He developed  the multifunctional  neuroprotective and neurorestorative  anti-Alzheimer drug,  Ladostigil ( TV 3326,  Phase IIa clinical studies) and M30 series under development for Alzheimer’s disease, ALS and Huntington Disease as neurorestorative drugs. He has published more than 800 scientific articles and edited 45 books and  has been on the Editorial Board of 43 International scientific journals.  He has over 100 patents as consequence of his drug development. He  has received  numerous major prizes, awards and honours from Israel, U.S., England, Germany,  China, Hong Kong, Iran, Denmark, Holland and Switzerland, several Honoary Doctorate of Philosophy, Honorary Causa, from universities of  Semmelweis University (Hungary)  and Pisa (Italy).  From 1991-1999, he was  the prestigious  Fogarty International Scholar-in-Residence at the Fogarty International Center for Advanced Study in the Human Health Sciences program of the National Institute of Health in Bethesda (USA). He is elected member of Leopoldina German Academy of Sciences and a Fellow of American College of Neuropsychopharmacology.

 

   
  Supporting Partner  
Sanofi Aventis
   
  Supporting Partner  
Queensland Government
   
OHMR
Copyright 2007 by ICMAN5 Login Sitemap Privacy Statement Legal Notice Copyright Disclaimer